MARKSANS PHARMA Q2 FY27 CONCALL: GUIDES 21–22% FY27 EBITDA MARGIN, TARGETS ₹4,000 CR FY28 REVENUE, ₹5,000 CR IN 3 YEARS & ₹6,000 CR IN 5 YEARS; PLANS EUROPEAN ACQUISITIONS & MANUFACTURING EXPANSION